Our clinical studies

Frequency and Intensity of local reactions in patients treated with 4% 5-FU vs 4% 5-FU associated with an emollient cream: a randomised, controlled clinical trial

Phase I dose escalation and dose expansion, international, multicenter study of W0180 as single agent and in combination with pembrolizumab (anti-PD-1) in adult participants with locally advanced or metastatic solid tumors.

A retrospective non interventional study on first line treatment for patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) (CAPSTAN CRC)

Neratinib in patients with HER2+ breast cancer: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Switzerland, Germany and Austria. rEal-LifE pAN-HER-blOckade with neRatinib: ELEANOR

Phase 2, open-label, single arm, multicenter study of Encorafenib, Binimetinib plus Cetuximab in subjects with previously untreated BRAFV600E -mutant metastatic colorectal cancer

Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors. International, multicenter, open label study.